Grade I or II Essential Hypertension Clinical Trial
Official title:
A Randomized, Double-Blind, Multicenter, Phase 2/3 Study to Evaluate the Efficacy and Safety of Combined Administration of TAK-536CCB (Fix-dose Combination of Azilsartan and Amlodipine) and Hydrochlorothiazide in Comparison With TAK-536CCB or Hydrochlorothiazide Monotherapy in Patients With Grade I or II Essential Hypertension
The objective of this study is to compare the efficacy and safety of combined administration of TAK-536CCB (Fix-dose combination of Azilsartan and Amlodipine) and Hydrochlorothiazide (HCTZ) with those of TAK-536CCB in patients with Grade I or II essential hypertension.
This study is a randomized, double-blind, multicenter, phase 2/3 study to evaluate the
efficacy and safety of combined administration of TAK-536CCB and Hydrochlorothiazide (HCTZ)
with those of TAK-536CCB or Hydrochlorothiazide in patients with grade I or II essential
hypertension.
This study consists of a 4-week single-blind placebo run-in period and a 10-week
double-blind treatment period.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment